Ozempic on TikTok: what Brazilian pharma creators get right and wrong

What's this video probably claiming?

@biaafarma is a Brazilian pharmacist creator, and videos captioned "Como usar a ozempic" ("How to use Ozempic") in this format almost always walk viewers through injection technique, the dose escalation schedule, storage requirements, and side effect management. That's the bread and butter of pharmacy-adjacent TikTok content in Brazil, where semaglutide prescribing has exploded since ANVISA approved Ozempic for type 2 diabetes and, more recently, Wegovy for obesity. The hashtags confirm this is aimed at a general consumer audience rather than healthcare professionals. Expect the video to cover pen setup, subcutaneous injection sites, what to do if you miss a dose, and probably some reassurance about nausea. Whether the creator stays in their lane as an educator versus drifting into prescriptive territory is the real question here.

What does the science actually show?

The clinical foundation for semaglutide is genuinely solid. The SUSTAIN trial program established that weekly 0.5 mg and 1 mg subcutaneous semaglutide reduced HbA1c by roughly 1.5 to 1.8 percentage points versus placebo in type 2 diabetes populations (Marso et al., 2016, NEJM). The STEP 1 trial, which is the one that put semaglutide on the weight-loss map, showed 14.9% mean body weight reduction over 68 weeks with 2.4 mg weekly dosing versus 2.4% in the placebo group (Wilding et al., 2021, NEJM). Dose escalation, starting at 0.25 mg weekly for four weeks, then stepping up, exists specifically to reduce gastrointestinal adverse events, which affect roughly 40 to 44% of users to some degree. Storage matters too: unopened pens need refrigeration at 2 to 8 degrees Celsius, and in-use pens are stable at room temperature below 30 degrees for up to 56 days.

Where does the social media noise diverge from clinical reality?

The gaps tend to cluster around a few recurring problems. First, pharmacist creators, even licensed ones, sometimes conflate the diabetes indication (Ozempic, up to 2 mg) with the obesity indication (Wegovy, 2.4 mg), implying interchangeability that regulators explicitly do not endorse. Compounded semaglutide is a separate and legally fraught category that should not be presented as equivalent to brand-name products, full stop. Second, the side effect conversation on TikTok is systematically incomplete. Gastroparesis risk, a documented concern flagged in post-marketing surveillance and explored by Sodhi et al. (2023, JAMA), rarely makes these videos. Neither does the thyroid C-cell tumor signal observed in rodent studies, which the FDA mandates as a black box warning. Third, injection technique videos sometimes miss the importance of rotating sites to prevent lipohypertrophy, which can reduce absorption predictability.

What should you actually know?

If you are watching a TikTok video to learn how to use Ozempic, you are already operating outside a safe information framework. Semaglutide requires a prescription in Brazil and virtually every other country for a reason: dosing decisions depend on your individual metabolic profile, kidney function, history of pancreatitis, and other factors a pharmacist on TikTok cannot assess. The SCALE and STEP trial data are impressive, but those results came from participants under structured clinical supervision with regular monitoring. Real-world adherence data is thinner and less flattering. A 2023 analysis published in Obesity by Ghusn et al. found that discontinuation rates at 12 months in real-world settings were significantly higher than in trials, often due to unmanaged side effects or cost. Use these videos to get general literacy, then have an actual clinical conversation before touching a pen.